在实验室进化的尿病原菌大肠杆菌 (Escherichia coli) 中共享的多药耐药性机制
Nakjun Choi1, Eunna Choi1, Yong-Joon Cho2
1Department of Life Sciences, School of Life Sciences and Biotechnology, Korea University, Seoul, South Korea.
Virulence
|June 20, 2024
概括
耐多药性Uropathogenic Escherichia coli (UPEC) 菌株通过特定基因的突变发展出对安培素的耐药性. 这些突变还使其对其他抗生素产生交叉耐药性,使治疗复杂化.
科学领域:
- 微生物学 微生物学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多抗药性细菌,特别是尿病原性大肠杆菌 (UPEC),构成了全球重大健康挑战.
- UPEC是尿路感染的主要原因,通常与多药性耐药性和复发性感染有关.
研究的目的:
- 调查UPEC. ampicillin耐药性的基因机制.
- 了解UPEC如何获得对β-乳糖抗生素的耐药性.
主要方法:
- 通过实验室暴露生成抗安培素的UPEC菌株 (低AmpR和高AmpR).
- 全基因组测序用于识别耐药菌株中的突变.
- 蛋白质建模和qRT-PCR用于验证已识别的突变的功能影响.
主要成果:
- 在低AmpR和高AmpR菌株中发现了marR,acrR和envZ基因的突变.
- 在High AmpR菌株中观察到nlpD基因的额外突变.
- 这些突变导致膜透率降低,多药物排泄表达增加,并抑制细胞溶解.
- 抗白素的UPEC菌株在小鼠模型中显示出减少了清除细菌负担的有效性.
- 获得的安皮西林耐药性与对其他类抗生素的交叉耐药性相关.
结论:
- 通过改变细胞过程,特定的遗传突变在UPEC中赋予了安培素耐药性.
- 在UPEC中抗西林耐药性与增加的多药耐药性有关,这给治疗带来了挑战.
- 这项研究突出了细菌获得交叉抗性的常见途径.
相关概念视频
Antibiotic Selection
53.1K
Overview
53.1K
Defense Against Bacterial Pathogens
1.4K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.4K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


